Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Aftertreated polymer (e.g., grafting, blocking, etc.)

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424780080 - SOLID SYNTHETIC ORGANIC POLYMER AS DESIGNATED ORGANIC ACTIVE INGREDIENT (DOAI)

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424780180 Polymer derived from ethylenic monomers only 85
424780300 Heterocyclic monomer 39
Entries
DocumentTitleDate
20090196847QUATERNARY AMMONIUM FUNCTIONALIZED GLYCODENDRIMERS, METHODS FOR THE PRODUCTION AND USE THEREOF - The present invention provides novel antimicrobial agents that are quaternary ammonium functionalized glycodendrimers. In one embodiment, the quaternary ammonium functionalized glycodendrimers are compounds of Formula (I): (Q08-06-2009
20110195041ANTIMICROBIAL COMPOSITIONS - Provided are antimicrobial compositions including at least one biocide covalently bound to a polyurethane. The biocide moiety may comprise triclosan, a triclosan derivative, or a quaternary ammonium salt. Further provided are methods of reducing biofilm formation or microbial growth on a surface, the method including applying to the surface an antimicrobial composition including at least one biocide covalently attached to a polyurethane.08-11-2011
20090214461Polymer particle dispersion, cosmetic composition comprising it and cosmetic process using it - The present disclosure relates to a cosmetic composition comprising, in a cosmetically acceptable medium, at least one dispersion of polymer particles in a liquid silicone medium, the polymer being a copolymer comprising at least one first block that is soluble and at least one second block that is insoluble in the silicone medium.08-27-2009
20130078210CHITOSAN DERIVATIVES FOR INACTIVATION OF ENDOTOXINS AND SURFACE PROTECTION OF NANOPARTICLES - The present disclosure provides a polymer comprising a derivative of chitosan, wherein the derivative is zwitterionic, as well as methods of using the polymer. In addition, the present disclosure provides a nanoparticle structure comprising a derivative of chitosan and a dendrimer, as well as methods of utilizing the nanoparticle structure.03-28-2013
20130084261POLY(BETA MALIC ACID) WITH PENDANT LEU-LEU-LEU TRIPEPTIDE FOR EFFECTIVE CYTOPLASMIC DRUG DELIVERY - The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer.04-04-2013
20100098653ANTIOXIDANT POLYMERS CONTAINING [1,2]-DITHIOLANE MOIETIES AND USES THEREOF - The present invention describes polymers containing 1,2-dithiolanes capable of acting as scavengers of free radicals, metals and reactive oxygen species. Also described are methods of synthesizing the antioxidant 1,2-dithiolane derivatives and polymerization thereof to produce biodegradable antioxidant polymers. The antioxidant polymers of the present invention may be used to treat diseases or conditions caused by oxidative stress and other free radical mediated conditions. The antioxidant polymers may also be used for the preparation of antioxidant particulate delivery devices of therapeutic agents.04-22-2010
20090155201Alkylated poly(allylamine) polymers and methods of use - The invention relates to a method for removing bile salts from a patient in need thereof and compositions useful in the method. The method comprises administering to the patient a therapeutically effective amount of a salt of an alkylated and crosslinked polymer. The alkylated and crosslinked polymer salt comprises the reaction product of crosslinked polymers, or salts and copolymers thereof having amine containing repeat units, with at least one aliphatic alkylating agent.06-18-2009
20080274075Poly(Ethylene Glycol) Derivatives and Process For Their Coupling to Proteins - Novel compounds, including PEGylated proteins of the formula, methods for preparing such compounds, methods of using such compounds, and other compositions and methods, are provided.11-06-2008
20100330025Surface Independent, Surface-Modifying, Multifunctional Coatings and Applications Thereof - The invention provides surface treatments that reduce or eliminate marine biofouling of various surfaces. A surface that is to be subjected to a marine environment can be treated with a mPEG-DOPA. The treated surface is thus rendered less susceptible to fouling of the surface.12-30-2010
20130028856Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions - Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders. In one example, the products include an additional agent or treatment. Such products can be used in methods for administering the products to treat the hyaluronan-associated diseases and conditions, for example, hyaluronan-associated cancers, for example, hyaluronan-rich tumors. The methods include administration of the hyaluronan degrading enzyme composition alone or in combination with other treatments. Also provided are methods and compositions for providing sustained treatment effects in hyaluronan-associated diseases and conditions.01-31-2013
20100068169MONOLITHIC DRUG DELIVERY SYSTEM - This invention relates to an improved monolithic drug delivery dosage form which releases a pharmaceutically active agent at a predetermined rate. The dosage form comprises a salted-out or crosslinked polymer and a pharmaceutically active agent. The salted-out or crosslinked polymer functions to polymerically entangle the pharmaceutically active agent but, progressively relax on contact with an aqueous medium in use to release the pharmaceutically active agent at a predetermined rate.03-18-2010
20130089511ABSORBABLE POLYMER FORMULATIONS - A co-polyester which includes the reaction product of a polycondensation polyester and epsilon-caprolactone, wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and a diol. The co-polyester is injectable and absorbable into animal, such as human, tissue and can be used for facial cosmetic or reconstructive surgery of soft tissue. Another embodiment is directed to a method for preventing adhesion using a co-polyester comprising the reaction product of a polycondensation polyester and epsilon-caprolactone, wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and a diol, and the co-polyester comprises about 40 to 50% by weight of the polycondensation polyester based on the total weight of the co-polyester.04-11-2013
20130052154Compositions and Methods for the Treatment of Lung Inflammation - Compositions and methods for the treatment of inflammation are provided.02-28-2013
20090041714Polymer-factor VIII moiety conjugates - Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.02-12-2009
20110038828MATRIX COMPOSED OF A NATURALLY-OCCURRING PROTEIN BACKBONE CROSS LINKED BY A SYNTHETIC POLYMER AND METHODS OF GENERATING AND USING SAME - A method of treating a disorder characterized by tissue damage is provided. The method comprising providing to a subject in need-thereof a composition which comprises a synthetic polymer attached to denatured fibrinogen or a therapeutic portion of the fibrinogen, the composition being formulated for releasing the therapeutic portion of the fibrinogen in a pharmacokinetically regulated manner, thereby treating the disorder characterized by tissue damage or malformation.02-17-2011
20090257975Solid and Semi-Solid Polymeric Ionic Conjugates - Aqueous solubility of drugs including insoluble or poorly soluble drugs such as ziprasidone is improved using a functional polymer to form an ionic conjugate with said drug.10-15-2009
20090252700Hydroxyphenyl cross-linked macromolecular network and applications thereof - A synthetic nucleus pulposus is provided that is useful in treatment of degenerative disc disease, augmentation of a degenerate disc, and alleviation of back pain. In an embodiment the synthetic nucleus pulposus comprises hyaluronan macromolecules that have been cross-linked via dihydroxyphenyl linkages. The synthetic nucleus pulposus restores or improves the water-retention capability of the disc. A method of treating an intervertebral disc with the cross-linked hyaluronan macromolecules is also provided. A method of regenerative therapy to address loss of cells of nucleus pulposus of an intervertebral disc based on treatment with the cross-linked hyaluronan macromolecules and mesenchymal stem cells is also provided.10-08-2009
20090123412Methods and compositions for stabilizing the myocardium - The present invention provides materials and methods that can serve as a prosthetic and/or, for tissue engineer applications, as a supporting matrix in the stabilization of the myocardium.05-14-2009
20090028813Methods for Treating Body Tissue - Methods of treating body tissue including repairing defects in body tissue as well as augmenting body tissue. Body tissue defects are repaired by injecting a polymeric adhesive composition through an injector into the region of the defect and allowing the adhesive composition to cure to repair the defect or to form an implant that adheres to at least one surface tissue in the region of the defect. Body tissue is augmented by filling a defect void with a polymeric adhesive composition and allowing it to cure.01-29-2009
20110027217IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS - This invention relates to compositions, and related compounds and methods, of conjugates of immunomodulatory agents and polymers or unit(s) thereof. The conjugates may be contained within synthetic nanocarriers, and the immunomodulatory agents may be released from the synthetic nanocarriers in a pH sensitive manner.02-03-2011
20090130050Titanium Oxide Composite Particles, Dispersion Liquid Thereof, and Process for Producing Them - Disclosed are titanium oxide composite particles and a dispersion of the titanium oxide composite particles, which can improve retentivity in blood and accumulation in cancer cells while satisfactorily developing the catalytic activity of titanium oxide particles to be excited upon exposure to ultrasonic waves or ultraviolet light. The titanium oxide composite particles comprise titanium oxide particles; and a nonionic hydrophilic polymer bound to the surface of the titanium oxide particles through at least one functional group selected from carboxyl-group, amino group, diol group, salicylic acid group, and phosphoric acid group. The composite particles can be rendered cytotoxic upon ultrasonic or ultraviolet irradiation to efficiently kill cells to be killed, such as cancer cells.05-21-2009
20100068170LOCAL DELIVERY OF WATER-SOLUBLE OR WATER-INSOLUBLE THERAPEUTIC AGENTS TO THE SURFACE OF BODY LUMENS - A method and device for local delivery of water-soluble or water-insoluble therapeutic agents to the surface of a normal or diseased body lumen is disclosed. An expandable structure of a medical disposable device, such as a balloon of a balloon catheter, is coated with an amphiphilic polymer coating comprising a therapeutic agent and an amphiphilic polymer or co-polymer. The medical disposable device is inserted into a body lumen, and expanded to contact the amphiphilic polymer coating against the body lumen. The total solubility of the polymer or co-polymer in vivo prevents any embolic hazard associated with the amphiphilic polymer coating.03-18-2010
20110200550Multi-Arm Polymeric Alkanoate Conjugates - Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the same. Methods of treatment employing such conjugates and related uses are also provided. The conjugates are prepared with high drug loading efficiencies.08-18-2011
20100098654TREATMENT OF NEUROBLASTOMA WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN - The present invention relates to methods of treatment of neuroblastoma. The present invention includes administering polymeric prodrugs of 7-ethyl-10-hydroxycamptothecin to patients in need thereof.04-22-2010
20090274643Low viscosity, high molecular weight linear random-block silicone polyalkyleneoxide copolymers - The present invention describes novel non-hydrolyzable, linear, random block copolymers comprising units of polysiloxanes and polyalkyleneoxides linked by bis-aminofunctional groups. These copolymers have been successfully applied as textile enhancers as well as conditioning agents for hair and skin care products.11-05-2009
20110171161POLYMER CONJUGATES OF PROTEGRIN PEPTIDES - The invention provides protegrin that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention has enhanced half-life and/or reduced clearance.07-14-2011
20110171165POLYMER CONJUGATES OF OPIOID GROWTH FACTOR PEPTIDES - The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.07-14-2011
20110171164POLYMER CONJUGATES OF GLP-2-LIKE PEPTIDES - The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer.07-14-2011
20110171163POLYMER CONJUGATES OF ZICONOTIDE PEPTIDES - The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer.07-14-2011
20110171162POLYMER CONJUGATES OF THYMOSIN ALPHA 1 PEPTIDES - The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer.07-14-2011
20080206182Conjugates of a Polymer and a Protein Linked by an Oxime Group - The present invention relates to polymers functionalized by an aminooxy group or a derivative thereof, conjugates, wherein the functionalized polymers are covalently coupled with a protein by an oxime linking group, a process for preparing the functionalized polymers, a process for preparing the conjugates, functionalize polymers as obtainable by the process of the present invention, conjugates as obtainable by the process of the present invention, and pharmaceutical compositions comprising at least one conjugate of the present invention and the use of said conjugates and compositions for the prophylaxis or therapy of the human or animal body.08-28-2008
20080206183Method of Preparing Grafted Polylysine Dendrimers - The use of monomers of active a-amino acids for the preparation of hydrophobic polypeptides in the form of precipitates, whereby the polypeptides result from the polymerization of the aforementioned monomers of active a-amino acids in an aqueous solvent and can be resolubilized in the solvent.08-28-2008
20110171166POLYMER CONJUGATES OF OSTEOCALCIN PEPTIDES - The invention provides osteocalcin that is chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.07-14-2011
20110171160POLYMER CONJUGATES OF KISS1 PEPTIDES - The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer.07-14-2011
20110206633POLYMER CONJUGATES OF CD-NP PEPTIDES - The invention provides CD-NP peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer.08-25-2011
20090162313High-Molecular Weight Conjugate of Podophyllotoxins - [PROBLEMS] A novel podophyllotoxin derivative, which is capable of releasing a drug without depending on biological enzymes and can be expected to have an effective therapeutic effect and is soluble in water has been demanded.06-25-2009
20090263346Systems and methods for delivery of drugs - Systems and methods for delivering drugs. Crystalline polymeric systems, referred to as CYC carriers, are associated with the drugs, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which results in relatively low and sharp melting temperatures. One class of CYC carriers, referred to as CYSC polymers, have a majority of the crystallizable side chains pendant from the polymer backbone. Another class of CYC carriers, referred to as ECC polymers, have a majority of the crystallizable side chains attached to terminal units of the polymer backbone. The ECC polymers can for example be obtained by modification of PLGA polymers. The CYC carriers in another class are non-polymeric. Some CYC carriers, referred to as CYC assemblies, have enhanced crystallinity as a result of the physical association of crystallizable moieties which are present in different types of molecule, for example between a polymer containing crystallizable moieties and a monomer containing crystallizable moieties. Preferably the CYC carrier is bioerodable.10-22-2009
20080317701Phosphate Ion Adsorbent - The present invention is directed to a phosphate ion adsorbent comprising a polymer or a salt thereof with a metal complex group represented by the following general formula (II):12-25-2008
20110142787POLYMERIZED CYCLIC NITROXIDE RADICAL COMPOUND AND USE THEREOF - A method of covalently bonding a cyclic nitroxide radical compound to a hydrophobic block of a specific hydrophylic-phobic block copolymer, and polymerized cyclic nitroxide radical compound copolymerized in this manner, as well as use of such a compound, for instance, in the medical field are provided. The compound demonstrates long term stability in vivo under reductive environment.06-16-2011
20110223127SDF-1 Binding Nucleic Acids And The Use Thereof - The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells.09-15-2011
20120195846DEGRADABLE HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) ACRYLATES AND GELS AND CONJUGATES DERIVED THEREFROM - A heterobifunctional poly(ethylene glycol) is provided having a hydrolytically degradable linkage, a first terminus comprising an acrylate group, and a second terminus comprising a target such as a protein or pharmaceutical agent or a reactive moiety capable of coupling to a target. Hydrogels can be prepared. The hydrogels can be used as a carrier for a protein or a pharmaceutical agent that can be readily released in a controlled fashion.08-02-2012
20120171154 PURIFICATION OF MULTI-SPECIFIC RECEPTORS - Disclosed is a method for preparing a composition enriched for receptors (typically molecular impringet polymers, MIPs) that bind an agent, where said receptors each specifically bind at least two discrete sites on said agent, by subjecting a sample of receptors to a first step of affinity purification with the agent where one binding site on the agent is non-accessible for binding to the receptors and subsequently subjecting the purified receptors to at least one further step of affinity purification with the agent where a second binding site on the agent is non-accessible. Also disclosed is a method for treatment, amelioration or prophylaxis of a disease selected from the group consisting of phenylketonuria (PKU, Følling's disease), hyperphenylalaninemia (HPA), alcaptonuria (black urine disease), tyrosinemia, hypertyrosinemia, myasthenia gravis, histidinemia, urocanic aciduria, maple syrup urine disease (MSUD), isovaleric acidemia (isovaleryl-CoA dehydrogenase deficiency), homocystinuria, propionic acidemia, methylmalonic acidemia, and glutaric aciduria Type 1 (GA-I), galactosemia, comprising administering to the gastrointestinal tract of a patient in need thereof an effective amount of a composition of molecular imprinted polymers (MIPs), said composition being capable of binding a symptom provoking agent of said disease.07-05-2012
20110110881LIQUID COMPOSITION OF CISPLATIN COORDINATION COMPOUND - A liquid composition containing a polymer micelle and having a pH values of 3.0 to 7.0 is provided. The micelle is constituted of a coordination compound having a block copolymer of polyethylene glycol and polyglutamic acid and cisplatin that is coordinate-bonded to the block copolymer.05-12-2011
20100135949ANTIMICROBIAL COMPOSITIONS - Antimicrobial compositions and methods are disclosed. The antimicrobial compositions are particularly useful in providing antimicrobial capability to a wide-range of medical devices. In one aspect the invention relates a UV curable antimicrobial coating comprising a UV curable composition comprising an oligomer, a momoner, and a photoinitiator which are together capable of forming a UV curable polymer composition. The compositions include rheology modifiers as necessary. The compositions also include antimicrobial agents, which may be selected from a wide array of agents. Representative antimicrobial agents include cetyl pyridium chloride, cetrimide, alexidine, chlorexidine diacetate, benzalkonium chloride, and o-phthalaldehyde.06-03-2010
20090074705Process for forming metal nanoparticles in polymers - A one step process is described for forming metal nanoparticles in polymers at atmospheric pressure and room temperature or with mild heating and stirring. The inventive process includes addition of nanoparticle precursor salts, e.g. HAuCl03-19-2009
20100310497PHARMACEUTICAL COMPOSITION OR COMBINATION DRUG - A pharmaceutical composition or combination drug, which contains, as active ingredients, (a) a coordination compound composed of a block copolymer represented by the following formula I or formula II and cisplatin, and (b) gemcitabine hydrochloride.12-09-2010
20100310496METHOD OF PRODUCING AMINO ACID-MODIFIED ORGANOPOLYSILOXANE EMULSIONS - The present invention relates to an amino acid-modified organopolysiloxane emulsion obtainable by reacting (a) a carboxy-unprotected amino acid, and (b) organopolysiloxane having an epoxy group in the molecule in an aqueous medium in the presence of a surfactant, is incorporated in a cosmetic product. The present invention also relates to the simple and highly efficient production of emulsions of amino acid-modified polysiloxane, as well as the use of the emulsions as beautifying components.12-09-2010
20110243880MODIFIED POLYMERS FOR DELIVERY OF POLYNUCLEOTIDES, METHOD OF MANUFACTURE, AND METHODS OF USE THEREOF - A polynucleotide delivery vehicle comprising a modified polymer is provided herein, the modified polymer having the following formula:10-06-2011
20110212049POLYMER COMPOSITIONS OF DIHYDROXYACETONE AND USES THEREOF - The present disclosure provides injectable synthetic and biodegradable polymeric biomaterials that effectively prevent seroma, a common postoperative complication following ablative and reconstructive surgeries. Provided biomaterials include physically crosslinked hydrogels that are thixotropic, display rapid chain relaxation, are easily extruded through narrow gauge needles, biodegrade into inert products, are well tolerated by soft tissues, and effectively prevent seroma in a radical breast mastectomy animal model.09-01-2011
20100055067PERFLUOROCARBON CONJUGATE AS A BLOOD SUBSTITUTE - There are provided disclosures relating to a conjugate of a perfluorocarbon compound and a cationic polymer wherein the conjugate is a blood substitute.03-04-2010
20090104143Hyaluronic acid containing bioconjugates: targeted delivery of anti-cancer drugs to cancer cells - A cell-targeted polymeric drug delivery system was designed based on the specific interaction between hyaluronic acid (HA) and its cell surface receptors overexpressed on cancer cell surface. The invention relates to compounds composed of a carrier molecule, wherein the carrier molecule contains at least one residue of an anti-cancer agent and at least one residue of a hyaluronic acid. The invention also relates to methods of making and using the compounds thereof.04-23-2009
20110081310COMPOSITIONS COMPRISING SUPERHYDROPHILIC AMPHIPHILIC COPOLYMERS AND METHODS OF USE THEREOF - Provided are healthcare compositions comprising a superhydrophilic amphiphilic copolymer and a cosmetically-acceptable or pharmaceutically-acceptable carrier. Also, provided are methods of cleansing or treating the human body by applying healthcare compositions of the present inventions to the body.04-07-2011
20110250163MONO- AND DI-PEG IL-10 PRODUCTION; AND USES - Provided are methods of producing a mixture of mono- and di-pegylated IL-IO.10-13-2011
20110250162DISINFECTING AND DETOXIFYING META-ARAMID PARTICLES - Porous, permeable particles of meta-aramid can be chlorinated or brominated to produce antimicrobial and detoxifying particles for use in applications such as, but not limited to, nonwoven webs, paper, textiles, absorbent articles, healthcare products, paints, filter materials, powder coatings, clear coatings, molded plastic articles, binders for fibrous materials, and the like. The particles can be charged with halogen before or after incorporation into the application medium. The particles can contain blends of meta-aramid with other polymers such as, but not limited to, cellulose, cellulose acetate, polyurethane, and the like. The particles will be effective at inactivation of pathogenic and odor-causing microorganisms and toxic chemical agents. The particles, which contain N-halamine units, have unexpected resistance to ultraviolet light degradation.10-13-2011
20110212047Polymer Therapy for the Treatment of Chronic Microvascular Diseases - Methods are provided for the treatment of chronic microvascular diseases characterized by inflammation, such as age-related macular degeneration, by administering a polyoxyethylene/polyoxypropylene copolymer. Although a single dose can be effective, multiple treatments can be administered to achieve an optimal and sustained effect. Preferably, a single administration followed by repeated weekly administration of the pharmaceutical composition, but not continuous infusion, achieves a desired effect. Methods of diagnosis and characterization of chronic microvascular diseases using the copolymer are also provided.09-01-2011
20110212048POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM - A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions. Polyethylene glycol groups are attached to extend the drug system's circulation half-life. In addition, fluorescent reported groups can be readily included to aid in visualizing and confirming drug system targeting. The drug system can deliver treatments for a wide range of diseases and is specially advantageous for treatment of neoplasms.09-01-2011
20090324535MODIFIED MACROMOLECULE - The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups.12-31-2009
20110165112POLYMER CONJUGATES OF C-PEPTIDES - The invention provides pro insulin c-peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer.07-07-2011
20110165113POLYMER CONJUGATES OF V681-LIKE PEPTIDES - The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.07-07-2011
20110165111POLYMER CONJUGATES OF NESIRITIDE PEPTIDES - The invention provides nesiritide that is chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of nesiritide not attached to the water-soluble oligomer.07-07-2011
20080206184Chemically Modified Protein Compositions and Methods - The present invention broadly relates to the field of protein modification and more specifically, water soluble block polymers, their attachment to drugs, and methods of making and use thereof.08-28-2008
20110262381FORMULATION FOR TREATMENT OF VAGINAL DRYNESS - The present invention is directed to a composition for treating vaginal dryness and lack of lubrication comprising: a poloxamer component; a phospholipid component; an optional oil component; and a non-aqueous carrier; wherein the composition is substantially anhydrous. In another aspect, the present invention is directed to a method of treating vaginal dryness comprising the step of administering to a patient suffering from vaginal dryness the above composition.10-27-2011
20110150820METHODS FOR COVALENTLY ATTACHING A POLYMER TO A METHIONINE RESIDUE IN PROTEINS AND PEPTIDES - Conjugates of polypeptides and a polymeric moiety such as PEG covalently attached to the sulfur atom of a methionine side chain are disclosed. Processes of preparing such conjugates, including intermediates and reagents utilized therefore are also disclosed. Further disclosed are therapeutic uses of these conjugates.06-23-2011
20100158851MATERIAL FOR FORMING A MULTI-LEVEL ANTIMICROBIAL SURFACE COATING AND ITS PREPARATION - The present invention provides a material for forming an antimicrobial surface coating with multi-level antimicrobial properties, which comprises one or more volatile or gaseous biocides, one or more nonvolatile biocides, and one or more polymers, wherein the volatile or gaseous biocides are encapsulated in the polymers to provide a sustained release of the volatile or gaseous biocides. The present invention further provides a method for preparing the material.06-24-2010
20110262380THEAPEUTIC USE OF PROTEIN-POLYMER CONJUGATES - This invention relates to use protein-polymer conjugates described in the specification to treat various diseases, including disease is idiopaic myelofibrsis, polycythaemia vera, and essential thromobocythaemia.10-27-2011
20100189679CROSSLINKED POLYALLYLAMINE OR ACID ADDITION SALT THEREOF, AND USE THEREOF FOR MEDICAL PURPOSES - A cross-linked polyallylamine or an acid addition salt thereof has both high phosphate adsorption capability and low degree of swelling, and a medical use thereof. The cross-linked polyallylamine or an acid addition salt thereof is obtained by copolymerization of allylammonium dihydrogen phosphate with an acid addition salt of N,N′-diallyl-1,3-diaminopropane in an amount of 5 to 25 mol % with respect to the amount of the allylammonium dihydrogen phosphate, the cross-linked polyallylamine or an acid addition salt thereof having a phosphate adsorption capacity of 2.7 to 5.0 mmol/g; and a degree of swelling of 2.0 to 5.0. The cross-linked polyallylamine or an acid addition salt thereof is useful as a therapeutic or prophylactic agent for hyperphosphatemia.07-29-2010
20100021416CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS - Disclosed herein are compositions and methods for the treatment of otic disorders with otic structure modulating compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).01-28-2010
20100068168THERMAL RESPONSIVE POLYMER SILOXANES, COMPOSITIONS, AND METHOD AND APPLICATIONS RELATED THERETO - The invention relates to materials comprising siloxanes, preferably the materials have thermal-responsive properties. In some embodiments, the invention relates to silsesquioxane groups functionalized with polymers. In another embodiment, silsequioxane-polymer conjugates comprise polylactone segments. The silsequioxane-polymer conjugates may be crosslinked together to form a material, and these materials may be functionalized with bioactive compounds so that the materials have desirable biocompatibility or bioactivity when used in medical devices. In further embodiments, the invention relates to composite materials that contain a polymer matrix and aggregates, and in some embodiments, methods of making, and methods of using these materials. Preferably, the aggregates are calcium phosphate aggregates. Preferably, the material is resistant to fracture. In further embodiments, the materials are used in surgical procedures of bone replacement. In further embodiments, the materials contain polyhedral silsesquioxanes and/or biodegradable segments.03-18-2010
20090208444Novel Formulation - A sanitising formulation comprising a solution of an acidic polymer and an anionic surfactant in a liquid vehicle. Suitable acidic polymers are those which include adjacent08-20-2009
20110318297SINGLE PROTEIN NANOCAPSULES FOR PROTEIN DELIVERY WITH LONG-TERM EFFECT - A protein nanocapsule having a single-protein core and a thin polymer shell anchored covalently to the protein core.12-29-2011
20120128623SURFACE ANTI-BIOMOLECULE AGENT - This invention discloses a surface anti-biomolecule agent for an artificially or naturally charged substrate. The anti-biomolecule agent comprises a copolymer employing anchoring blocks or domains to binds sites of the substrate via electrostatic attractive force, and employing zwitterionic blocks or domains extended outwardly to reduce the attachment of biomolecules to the substrate.05-24-2012
20120171153Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions - Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders. In one example, the products include an additional agent or treatment. Such products can be used in methods for administering the products to treat the hyaluronan-associated diseases and conditions, for example, hyaluronan-associated cancers, for example, hyaluronan-rich tumors. The methods include administration of the hyaluronan degrading enzyme composition alone or in combination with other treatments. Also provided are methods and compositions for providing sustained treatment effects in hyaluronan-associated diseases and conditions.07-05-2012
20120177593SYNTHESIS OF DENDRIMER CONJUGATES - The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.07-12-2012
20120177592DEGRADABLE THERMORESPONSIVE POLY(ETHYLENE GLYCOL) ANALOGUE MATERIALS - A method of developing degradable linear poly(ethylene glycol) PEG (DPEG) with multiple functioning capacities, which can be used as drug carriers for cancer cell delivery. A DPEG may be effective in targeting cancerous tumors through an enhanced permeation and retention effect (EPR). The DPEG will then degrade in the acidic extracellular fluid of solid tumors leading to fast cellular internalizations, finally degrading in the lysosome for efficient renal clearance. These may be used in conjunction with drugs and/or targeting groups. Furthermore, DPEGs are thermoresponsive, on an as needed basis, making them useful for in vivo application.07-12-2012
20120177594POLYION COMPLEX COMPRISING PHD2 EXPRESSION INHIBITING SUBSTANCE - The present invention aims to provide a gene delivery system with higher safety and higher sustainability, which is effective for the treatment of ischemic diseases and the like, and the like. The present invention provides a pharmaceutical composition containing, as an active ingredient, a polyanionic substance that suppresses expression of PHD2, and containing a polyion complex of the polyanionic substance and a polycation chargeable polymer.07-12-2012
20120315239ZWITTERIONIC POLYMER BIOCONJUGATES AND RELATED METHODS - Zwitterionic polymer and mixed charge copolymer bioconjugates, methods for making and using the bioconjugates.12-13-2012
20120258068SCAFFOLDS FORMED FROM POLYMER-PROTEIN CONJUGATES, METHODS OF GENERATING SAME AND USES THEREOF - Conjugates are provided herein which comprise a protein attached to at least two polymeric moieties, at least one of which exhibits reverse thermal gelation. The conjugates are suitable for being cross-linked by non-covalent and/or covalent cross-linking. Compositions-of-matter comprising cross-linked conjugates are provided herein, as well as processes for producing same. Methods of controlling a physical property of compositions-of-matter are also provided herein. The conjugates and compositions-of-matter may be used for various applications, such as cell growth, tissue formation, and treatment of disorders characterized by tissue damage or loss, as described herein.10-11-2012
20120082636STABILIZED ALPHA HELICAL PEPTIDES AND USES THEREOF - Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.04-05-2012
20120263672Biocompatible Adhesive Materials and Methods - Biocompatible adhesive materials, such as for use with biological tissues and/or medical implants, are provided, as well as methods and kits for making and using the biocompatible adhesive materials. The biocompatible adhesive materials include a dendrimer component and a polymer component, and may be tailored for specific tissue types and conditions.10-18-2012
20090016985POLYMERIC DRUG DELIVERY SYSTEM CONTAINING A MULTI-SUBSTITUTED AROMATIC MOIETY - The present invention provides polymeric delivery systems including a multi-substituted aromatic moiety. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed.01-15-2009
20110002874Polymer Network Compositions and Associated Methods - Biomimetic polymer networks comprising a heteropolymer network having a cavity, the cavity having a selective affinity for a moiety, methods for making biomimetic polymer networks, and methods for using biomimetic polymer networks.01-06-2011
20110044930COPOLYHYDROXYALKYLGLUTAMINES FUNCTIONALISED WITH HYDROPHOBIC GROUPS, AND USES THEREOF, ESPECIALLY IN THERAPEUTICS - The invention relates to novel biodegradable materials which are based on modified polyamino acids and which can be used for the vectorisation of active principle(s) (AP). The invention also relates to novel pharmaceutical, cosmetic, dietary or phytosanitary compositions based on said polyamino acids. The aim of the invention is to provide a novel polymer raw material which can be used for the vectorisation of active principles and which can optimally fulfil all required specifications in said area, namely: biocompatibility, biodegradability and the ability to become easily associated with many active principles or to solubilise said principles and to release same in vivo. Said aim is achieved with novel copolyhydroxyalkylglutamines comprising glutamine units and optionally glutamate units and bearing hydrophobic groups containing between 8 and 30 carbon atoms. Said copolyhydroxyalkylglutamines are amphiphilic and can be easily and economically transformed into particles for the vectorisation of active principles, whereby said particles can form stable aqueous colloidal suspensions.02-24-2011
20120321583Protein-Polymer-Drug Conjugates - A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L12-20-2012
20120328555DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER - The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.12-27-2012
20100203006DEVOLATILIZATION APPARATUS AND PROCESS - Embodiments of the invention provide an apparatus or process for devolatilization of flowable materials (such as molten polymers with entrained or dissolved solvent or unreacted monomers or comonomers) using a plate heater having heating channels, the design or operation of which heating channels maintains the flowable material above its bubble point pressure during passage through a larger first zone and then induces flashing in, or downstream of, a smaller second zone of the heating channel. The apparatus enables a higher throughput per heating channel while achieving equivalent or better devolatilization, as compared to current devolatilization apparatus.08-12-2010
20080247987Block Copolymer Compositions and Uses Thereof - The present invention describes compositions, devices, and methods for the production, use and administration of the composition having a non-thermoreversible block copolymer composition.10-09-2008
20130142752CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS - The present invention relates to biodegradable polymers (e.g., polyesters and polyester amides) derived from functionalized biologically active compounds that can provide site specific delivery of bioactive compounds upon biodegradation in a controlled manner.06-06-2013
20130129663REVERSE THERMAL GELS AND USES THEREFOR - Biodegradable triblock copolymer compositions are provided which are useful in tissue engineering and drug delivery. The copolymers are reverse thermal gels in that when heated from a lower temperature to a higher temperature, they gel. These gels are useful in drug delivery when complexed with an active agent. For example the compositions can be used for intraocular injection of active agents, such as anti-angiogenic agents for treatment of a maculopathy or retinitis.05-23-2013
20130129664Cancer Therapy Via Selective Uptake of Specialized Nanoparticles in Cancer Cells - Disclosed herein are polymer/fullerene nanoparticles that have selective uptake into cancer cells, and which, upon being taken into the cancer cells induce apoptosis. Induction of apoptosis can be controlled by activation of the nanoparticles. Activation can occur such as by photoactivation, or other means.05-23-2013
20110243881BIOCOMPATIBLE POLYMERS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM - A process for treating fibroses including administering a therapeutically effective amount of a pharmaceutical composition which includes at least one biocompatible polymer of the following general formula (I): A10-06-2011
20110236343Antimicrobial polysiloxane materials containing metal species - Polysiloxane-based materials, which include metal species, are provided. The polysiloxane-based compositions and materials generally include (i) amino-functional polysiloxane material and (ii) a plurality of metal species distributed within the polymeric material. Polymer based compositions in which the amino-functional polysiloxane material includes quaternary ammonium groups, e.g., tetraalkyl ammonium groups, are examples of suitable materials which may be used to form the present compositions. The metal species, which may be in an oxidized and/or neutral state, may be bonded, coordinated, chelated, suspended, and/or dispersed within the polymeric material.09-29-2011
20100316589Coated Pharmaceutical Compositions - The present invention relates to polycarbophil coated crosslinked amine polymers and/or pharmaceutical compositions comprising polycarbophil coated crosslinked amine polymers. The polycarbophil coated crosslinked amine polymers have several therapeutic applications, including, but not limited to, hyperphosphatemia, chronic kidney disease and End-Stage Renal Disease.12-16-2010
20100316588METHOD FOR COATING AN ELASTOMERIC MATERIAL WITH A LAYER OF ANTITOXIC MATERIAL - The invention relates to elastomeric products that are coated with a thin layer of elastomeric polymeric coating containing an antitoxic agent, particularly a demand disinfectant iodinated resin. The antimicrobial coated catheters are prepared by adding the antitoxic agent to a solution of a liquid elastomeric polymer and then coating the surface of the elastomeric through a dipping or spraying procedure. The antimicrobial coatings can be applied to a variety of different elastomeric products including gloves and catheters and are capable of providing a high level of protection against microbes and other contaminants.12-16-2010
20130121954Poly(vinyl ester) Polymers for In Vivo Nucleic Acid Delivery - The present invention is directed membrane active poly(vinyl ester) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cells in vivo. RNAi polynucleotides are conjugated to the poly(vinyl ester) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(vinyl ester) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.05-16-2013
20130189218PHARMACEUTICAL FORMULATIONS FOR FUMAGILLIN DERIVATIVE-PHF CONJUGATES - The invention described herein provides a mixture comprising polymer molecules or salts thereof, wherein a polymer molecule in the mixture comprises covalently bound subunits L, K, and M wherein the average molecular weight of the polymer molecules in the mixture is about 50 kDa to about 200 kDa, wherein the mole percentage of subunit M, K and L, relative to the total amount of subunits in the mixture, is about 90.5 to about 96 mol %, about 2.8 to about 7.3 mol %, and about 1.2 to about 2.2 mol %, respectively.07-25-2013
20120020911MATRIX COMPOSED OF A NATURALLY-OCCURRING PROTEIN BACKBONE CROSS LINKED BY A SYNTHETIC POLYMER AND METHODS OF GENERATING AND USING SAME - The present invention relates to biodegradable scaffolds composed of a naturally-occurring protein backbone cross-linked by a synthetic polymer. Specifically, the present invention provides PEGylated-fibrinogen scaffold and methods of generating and using same for treating disorders requiring tissue regeneration.01-26-2012
20120027714Segmented Polymers and Their Conjugates - Segmented water soluble polymers, containing a higher molecular weight segment linked to a lower molecular weight segment, are described. In one embodiment, the polymer segments are poly(ethylene glycol) segments. The segmented polymers are functionalized and are useful for conjugation to various moieties such as pharmacologically active substances. Also described are conjugates of such polymers and methods of their preparation.02-02-2012
20130101546Protein-Polymer-Drug Conjugates - A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L04-25-2013
20130202548IMMUNOMODULATORY PROTEIN CONSTRUCTS WITH A HELICAL POLYMERIC BACKBONE - The present invention relates to protein constructs that comprise one or more peptides, proteins, factors, compounds or other components as further described herein that are linked to and/or are linked to each other via a helical polymeric backbone. The constructs of the invention are suitable for administration to a human or animal body and can be used for pharmaceutical purposes, for example, for immunotherapy, such as for treating cancer and for other immunological applications, as well as for other therapeutic, prophylactic and/or diagnostic purposes.08-08-2013
20120093762NUCLEIC ACID DELIVERY COMPOUNDS - Polymers including two or more different recurring units are disclosed herein. Also disclosed herein are methods of using such polymers to deliver nucleic acids to a cell.04-19-2012
20120093761VACCINE COMPOSITIONS AND METHODS OF USE THEREOF - Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, siRNA, RNA or DNA to PAPCs or MHC class II positive cells (e.g. tumor cells). Antigens may be, for example, DNA that results in expression of the gene of interest and induction of a robust and specific immune response to the expressed protein in a subject (e.g., mammal). Antigens may also be immunogenic peptides or polypeptides that are processed and presented. In one embodiment, a nanoparticle -based method to deliver antigens in vivo as described herein includes injection of a vaccine composed of a DNA encoding at least one antigen, or at least one antigenic peptide or polypeptide conjugated to a charged dendrimer (e.g., PADRE-derivatized dendrimer) that is also conjugated to a T helper epitope (e.g., PADRE). Negatively-charged plasmids bind naturally to a positively-charged PADRE-dendrimer, while peptide or polypeptide antigens can be chemically linked to the PADRE-dendrimer if they are not negatively-charged. Alternatively, negatively-charged dendrimers may be used. The compositions, kits, vaccines and methods described herein have both prophylactic and treatment applications, i.e., can be used as a prophylactic to prevent onset of a disease or condition in a subject, as well as to treat a subject having a disease or condition. A vaccine as described herein can be used to mount an immune response against any infectious pathogen or cancer.04-19-2012
20130209390Process For Producing Drug-Block Copolymer Composite And Pharmaceutical Preparation Containing Same - [Problem] There has been a requirement for a process for producing a pharmaceutical preparation that is obtained by encapsulating a uniform poorly water-soluble drug in a block copolymer, and dissolves immediately with an addition of water, and does not contain residues of organic solvents.08-15-2013

Patent applications in class Aftertreated polymer (e.g., grafting, blocking, etc.)

Patent applications in all subclasses Aftertreated polymer (e.g., grafting, blocking, etc.)